EDMONTON, June 5 /CNW/ - BioMS Medical Corp (TSX: MS), a leading
developer of products for the treatment of multiple sclerosis (MS), today
announced that the first patients have been enrolled in MAESTRO-03, its U.S.
pivotal phase III clinical trial of MBP8298, a proprietary synthetic peptide
for the treatment of multiple sclerosis. The randomized, double-blind study is
enrolling approximately 510 secondary progressive MS patients at approximately
60 sites across the U.S. who will be administered either MBP8298 or placebo
intravenously every six months for a period of two years.
